# Zentalis Pharmaceuticals, Inc.: overview ZNTL · Nasdaq · CIK 1725160 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/zntl.md) · [Financials](/companies/zntl/financials.md) · [Filings](/companies/zntl/filings.md) · [Insiders](/companies/zntl/insiders.md) Latest reported revenue: [$0](/filings/0001725160-26-000014.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 26, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001725160-26-000014). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001725160-25-000161.md) | [26.9 d](/filings/0001725160-26-000014.md) | [0.0](/filings/0001725160-25-000105.md) | [0.0](/filings/0001725160-25-000149.md) | [0.0](/filings/0001725160-25-000161.md) | [0.0 d](/filings/0001725160-26-000014.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(185.6%) d](/filings/0001725160-26-000014.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | [(176.7%) d](/filings/0001725160-26-000014.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.56)](/filings/0001725160-25-000161.md) | not reported | [(0.67)](/filings/0001725160-26-000042.md) | [(0.37)](/filings/0001725160-26-000062.md) | [(0.37)](/filings/0001725160-25-000161.md) | not reported | [(0.50)](/filings/0001725160-26-000042.md) | [(0.59)](/filings/0001725160-26-000062.md) | | Free cash flow | $m | [(44.0) d](/filings/0001725160-25-000161.md) | [(39.7) d](/filings/0001725160-26-000014.md) | [(32.6)](/filings/0001725160-26-000042.md) | [(34.7) d](/filings/0001725160-26-000062.md) | [(27.0) d](/filings/0001725160-25-000161.md) | [(30.9) d](/filings/0001725160-26-000014.md) | [(33.0)](/filings/0001725160-26-000042.md) | [(37.2) d](/filings/0001725160-26-000062.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [0.0](/filings/0001725160-25-000067.md) | [0.0](/filings/0001725160-26-000014.md) | [67.4](/filings/0001725160-26-000014.md) | [0.0](/filings/0001725160-26-000014.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(283.6%)](/filings/0001725160-26-000014.md) | not reported | | Net margin | % | not reported | not reported | not reported | [(246.0%)](/filings/0001725160-26-000014.md) | not reported | | Diluted EPS | $ per share | [(3.72)](/filings/0001725160-24-000080.md) | [(4.48)](/filings/0001725160-25-000067.md) | [(4.47)](/filings/0001725160-26-000014.md) | [(2.33)](/filings/0001725160-26-000014.md) | [(1.91)](/filings/0001725160-26-000014.md) | | Free cash flow | $m | [(160)](/filings/0001725160-24-000080.md) | [(166)](/filings/0001725160-25-000067.md) | [(208)](/filings/0001725160-26-000014.md) | [(171)](/filings/0001725160-26-000014.md) | [(125)](/filings/0001725160-26-000014.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/zntl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [5AM Venture Management, LLC](/funds/1799883.md) | 2026-06-30 | $19.1m | 3,947,913 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $18.2m | 3,753,525 | | Added +2,483,688 | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $17.9m | 3,700,000 | | Added +69,000 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $14.7m | 3,024,936 | | Added +68,410 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $13.8m | 2,835,669 | | Added +524,962 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $11.1m | 2,298,403 | | Added +566,320 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $7.8m | 1,609,078 | | Reduced −329,067 | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $6.9m | 1,412,656 | | Unchanged | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $6.7m | 1,390,576 | | New +1,390,576 | | [Decheng Capital LLC](/funds/2010850.md) | 2026-06-30 | $6.4m | 1,323,327 | | Unchanged | ## Recent filings [All 539 filings](/companies/zntl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 16:09 ET | [8-K](/filings/0001628280-26-057112.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-057112 | | 2026-08-06 | 16:13 ET | [10-Q](/filings/0001725160-26-000062.md) | Quarterly report, period 2026-06-30 | 0001725160-26-000062 | | 2026-08-06 | 16:10 ET | [8-K](/filings/0001725160-26-000061.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001725160-26-000061 | | 2026-06-18 | 16:03 ET | [8-K](/filings/0001725160-26-000052.md) | 5.07 Shareholder vote results | 0001725160-26-000052 | | 2026-05-27 | 16:07 ET | [8-K](/filings/0001725160-26-000049.md) | 5.02 Departure or appointment of officers or directors | 0001725160-26-000049 | | 2026-05-21 | 17:29 ET | [8-K](/filings/0001725160-26-000045.md) | 7.01 Regulation FD disclosure; 8.01 Other events | 0001725160-26-000045 | | 2026-05-12 | 16:11 ET | [10-Q](/filings/0001725160-26-000042.md) | Quarterly report, period 2026-03-31 | 0001725160-26-000042 | | 2026-05-12 | 16:10 ET | [8-K](/filings/0001725160-26-000041.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001725160-26-000041 | | 2026-05-05 | 08:01 ET | [8-K](/filings/0001725160-26-000033.md) | 7.01 Regulation FD disclosure; 8.01 Other events | 0001725160-26-000033 | | 2026-04-30 | 16:06 ET | [DEF 14A](/filings/0001725160-26-000027.md) | Proxy statement, period 2026-06-16 | 0001725160-26-000027 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001725160-26-000014.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1725160 - Tickers: ZNTL - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:29 ET. No prices; not investment advice.